The mTOR inhibitor everolimus has proven anti-tumoral efficacy in several clinical phase 3 trials in patients with neuroendocrine tumors [39–41] and is approved for pancreatic, intestinal and pulmonary neuroendocrine tumors [42]. The gene discussed is MTOR; the disease is neuroendocrine neoplasm.